Basiliximab, previously known as CHI 621 and possessing the substance identifier 179045-86-4, represents a antibody agent utilized primarily in suppressing acute rejection following organ implantation. This modified antibody specifically binds to the interleukin-2 (IL-2) site, effectively blocking IL-2 pathway and subsequently diminishing the immun